DR-TB Drugs Under the Microscope - Sources and Prices for Drug-Resistant Tuberculosis Medicines. 2nd Edition, November 2012
(2012; 48 pages)

Resumen

This report focuses on just some of the many factors that hamper the scaling up of DR-TB treatment - the limited availability and high cost of quality-assured medicines for resistant strains of the disease, owing to an insecure market and insufficient demand; and the research questions that remain unsolved with existing medicines.Also, as the R&D pipeline prepares to deliver the first new compounds for TB in close to half a century, the report provides an initial assessment of the approaches to be taken in order to radically transform our ability to respond to this plague.

 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019